2025-521914-25-00CompletedPhase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy Participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Aug 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (actual)
- First submitted
- 30 Apr 2025
- Start date
- 31 Jul 2025
- Lead sponsor
- Clexio Biosciences Ltd.
- EU CT number
- 2025-521914-25-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 110
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Biotrial | Rennes | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.